{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:26:22Z","timestamp":1760189182313},"reference-count":97,"publisher":"Informa UK Limited","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2011,3,31]]},"DOI":"10.2217\/fon.10.167","type":"journal-article","created":{"date-parts":[[2011,2,16]],"date-time":"2011-02-16T19:56:29Z","timestamp":1297886189000},"page":"365-379","source":"Crossref","is-referenced-by-count":12,"title":["Bevacizumab and Its Use in Epithelial Ovarian Cancer"],"prefix":"10.1080","volume":"7","author":[{"given":"Ursula A","family":"Matulonis","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brooklyn Avenue, Boston, MA02215, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2011,3,21]]},"reference":[{"key":"e_1_3_2_3_1_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.20073"},{"key":"e_1_3_2_3_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra041842"},{"key":"e_1_3_2_3_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199601043340101"},{"key":"e_1_3_2_3_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.6.1895"},{"key":"e_1_3_2_3_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.1684"},{"key":"e_1_3_2_3_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2006.04.017"},{"key":"e_1_3_2_3_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa052985"},{"key":"e_1_3_2_3_8_1","unstructured":"Vergote I TropacupCG AmantFet al.: EORTC-GCG\/NCIC-CTG randomised trial comparing primary debulking surgery with neoadjuvant chemotherapy in stage IIIc\u2013IV ovarian fallopian tube and peritoneal cancer (OvCa).Presented at:International Gynecologic Cancer Society 2008 Meeting.Bangkok Thailand 25\u201328 October 2008."},{"key":"e_1_3_2_3_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61157-0"},{"key":"e_1_3_2_3_10_1","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1200\/jco.2010.28.18_suppl.lba5008","article-title":"Phase III trial of induction gemcitabine (G) or paclitaxel (T) plus carboplatin (C) followed by elective T consolidation in advanced ovarian cancer (OC): Final safety and efficacy report.","volume":"28","author":"Teneriello MG","year":"2010","unstructured":"Teneriello MG , GordonAN, LimPet al.: Phase III trial of induction gemcitabine (G) or paclitaxel (T) plus carboplatin (C) followed by elective T consolidation in advanced ovarian cancer (OC): Final safety and efficacy report.J. Clin. Oncol.28(Suppl.), S18 (2010).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_2_3_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.3.389"},{"key":"e_1_3_2_3_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)13718-X"},{"key":"e_1_3_2_3_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.0913"},{"key":"e_1_3_2_3_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.0282"},{"key":"e_1_3_2_3_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.7519"},{"key":"e_1_3_2_3_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.05.195"},{"key":"e_1_3_2_3_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1141"},{"key":"e_1_3_2_3_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2004.08.002"},{"key":"e_1_3_2_3_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2008.02.044"},{"key":"e_1_3_2_3_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.14.3312"},{"key":"e_1_3_2_3_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.6.2183"},{"key":"e_1_3_2_3_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.1.60"},{"key":"e_1_3_2_3_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2005.10.036"},{"key":"e_1_3_2_3_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1438.2005.00482.x"},{"key":"e_1_3_2_3_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-8258(02)00103-8"},{"key":"e_1_3_2_3_26_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2006.0078"},{"key":"e_1_3_2_3_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djh323"},{"key":"e_1_3_2_3_28_1","unstructured":"Gemcitabine package insert. Eli Lilly Ltd IN USA."},{"key":"e_1_3_2_3_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.4037"},{"key":"e_1_3_2_3_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2009.130"},{"key":"e_1_3_2_3_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.2777"},{"key":"e_1_3_2_3_32_1","doi-asserted-by":"crossref","unstructured":"Matei D SillMW DeGeestKet al.: Phase II trial of sorafenib in persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC): A Gynecology Oncology Group (GOG) study.J. Clin. Oncol.(Suppl. 26) (2008) (Abstract 5537).","DOI":"10.1200\/jco.2008.26.15_suppl.5537"},{"issue":"15","key":"e_1_3_2_3_33_1","article-title":"A randomized Phase II placebo-controlled trial using maintenance therapy to evaluate the vascular targeting agent BIBF 1120 following treatment of relapsed ovarian cancer (OC).","volume":"27","author":"Ledermann JA","year":"2009","unstructured":"Ledermann JA , RustinGJ, HackshawAet al.: A randomized Phase II placebo-controlled trial using maintenance therapy to evaluate the vascular targeting agent BIBF 1120 following treatment of relapsed ovarian cancer (OC).J. Clin. Oncol.27(Suppl. 15), (2009).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_2_3_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2007.25.18_suppl.5508"},{"issue":"15","key":"e_1_3_2_3_35_1","article-title":"Randomized, double-blind, placebo-controlled Phase II study of AMG 386 combined with weekly paclitaxel in patients (pts) with recurrent ovarian carcinoma.","volume":"28","author":"Karlan BY","year":"2010","unstructured":"Karlan BY , OzaAM, HansenVLet al.: Randomized, double-blind, placebo-controlled Phase II study of AMG 386 combined with weekly paclitaxel in patients (pts) with recurrent ovarian carcinoma.J. Clin. Oncol.28(Suppl. 15), (2010).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_2_3_36_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.6683"},{"key":"e_1_3_2_3_37_1","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.1993.2045"},{"issue":"20","key":"e_1_3_2_3_38_1","first-page":"4593","article-title":"Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders.","volume":"57","author":"Presta LG","year":"1997","unstructured":"Presta LG , ChenH, O\u2019ConnorSJet al.: Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders.Cancer Res.57(20), 4593\u20134599 (1997).","journal-title":"Cancer Res."},{"key":"e_1_3_2_3_39_1","doi-asserted-by":"publisher","DOI":"10.3109\/08977199209023937"},{"key":"e_1_3_2_3_40_1","unstructured":"Bevacizumab package insert Genetech CA USA."},{"key":"e_1_3_2_3_41_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.1509"},{"key":"e_1_3_2_3_42_1","doi-asserted-by":"publisher","DOI":"10.1038\/362841a0"},{"issue":"17","key":"e_1_3_2_3_43_1","first-page":"4032","article-title":"Complete inhibition of angiogenesis and growth or microtumors by anti-vascular endothelial growth factor neutralizing antibody: novel concepts of angiostatic therapy from intravital videomicroscopy.","volume":"56","author":"Borgstr\u00f6m P","year":"1996","unstructured":"Borgstr\u00f6m P , HillanKJ, SriramaraoP, FerraraN: Complete inhibition of angiogenesis and growth or microtumors by anti-vascular endothelial growth factor neutralizing antibody: novel concepts of angiostatic therapy from intravital videomicroscopy.Cancer Res.56(17), 4032\u20134039 (1996).","journal-title":"Cancer Res."},{"key":"e_1_3_2_3_44_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.25.14765"},{"key":"e_1_3_2_3_45_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032691"},{"key":"e_1_3_2_3_46_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.11.022"},{"key":"e_1_3_2_3_47_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.10.066"},{"key":"e_1_3_2_3_48_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.098"},{"key":"e_1_3_2_3_49_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa061884"},{"key":"e_1_3_2_3_50_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa072113"},{"key":"e_1_3_2_3_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61904-7"},{"key":"e_1_3_2_3_52_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.3055"},{"key":"e_1_3_2_3_53_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0706596"},{"key":"e_1_3_2_3_54_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.11.1088"},{"issue":"11","key":"e_1_3_2_3_55_1","first-page":"1385","article-title":"Analysis of blood vessel maturation processes during cyclic ovarian angiogenesis.","volume":"78","author":"Goede VM","year":"1998","unstructured":"Goede VM , SchmidtT, KimminaSet al.: Analysis of blood vessel maturation processes during cyclic ovarian angiogenesis.Lab. Invest.78(11), 1385\u20131394 (1998).","journal-title":"Lab. Invest."},{"key":"e_1_3_2_3_56_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm0603-669"},{"issue":"17","key":"e_1_3_2_3_57_1","first-page":"4032","article-title":"Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: novel concepts of angiostatic therapy from intravital videomicroscopy.","volume":"56","author":"Borgstrom P","year":"1996","unstructured":"Borgstrom P , HillanKJ, SriramaraoP, FerraraN: Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: novel concepts of angiostatic therapy from intravital videomicroscopy.Cancer Res.56(17), 4032\u20134039 (1996).","journal-title":"Cancer Res."},{"issue":"9","key":"e_1_3_2_3_58_1","first-page":"963","article-title":"Inhibition of growth and metastasis of ovarian carcinoma by administering a drug capable of interfering with vascular endothelial growth factor activity.","volume":"87","author":"Mu J","year":"1996","unstructured":"Mu J , AbeY, TsutsuiTet al.: Inhibition of growth and metastasis of ovarian carcinoma by administering a drug capable of interfering with vascular endothelial growth factor activity.Cancer Res.87(9), 963\u2013971 (1996).","journal-title":"Cancer Res."},{"key":"e_1_3_2_3_59_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-1888"},{"issue":"17","key":"e_1_3_2_3_60_1","first-page":"5224","article-title":"Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation.","volume":"63","author":"Belotti D","year":"2003","unstructured":"Belotti D , PaganoniP, ManentiLet al.: Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation.Cancer Res.63(17), 5224\u20135229 (2003).","journal-title":"Cancer Res."},{"key":"e_1_3_2_3_61_1","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-07-0366"},{"key":"e_1_3_2_3_62_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19990101)85:1<178::AID-CNCR25>3.0.CO;2-7"},{"key":"e_1_3_2_3_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2010.03.018"},{"key":"e_1_3_2_3_64_1","unstructured":"Quackenbush J FanJ-B HirschMet\u00a0al.: Molecular fingerprints and mechanisms of chemoresistance in ovarian cancer. AACR Meeting (2008) (Abstract 4128)."},{"key":"e_1_3_2_3_65_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.7900"},{"key":"e_1_3_2_3_66_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2010.28.18_suppl.lba1"},{"issue":"8","key":"e_1_3_2_3_67_1","article-title":"ICON7: a Phase II randomized Gynaecologic Cancer Intergroup Trial of concurrent bevacizumab and chemotherapy followed by maintenance bevacizumab versus chemotherapy alone in women with newly diagnosed epithelial ovarian, primary peritoneal or fallopian tube cancer.","volume":"21","author":"European Society of Medical Oncology","year":"2010","unstructured":"European Society of Medical Oncology; PerrenT, SwartAM, PfistererJet al.: ICON7: a Phase II randomized Gynaecologic Cancer Intergroup Trial of concurrent bevacizumab and chemotherapy followed by maintenance bevacizumab versus chemotherapy alone in women with newly diagnosed epithelial ovarian, primary peritoneal or fallopian tube cancer.Ann. Oncol.21(Suppl. 8), (2010).","journal-title":"Ann. Oncol."},{"key":"e_1_3_2_3_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2004.12.001"},{"key":"e_1_3_2_3_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2006.05.006"},{"key":"e_1_3_2_3_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2006.05.018"},{"key":"e_1_3_2_3_71_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.11.5345"},{"issue":"33","key":"e_1_3_2_3_72_1","first-page":"5100","article-title":"Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer.","volume":"2","author":"Cannistra SA","year":"2007","unstructured":"Cannistra SA , MatulonisUA, Penson, RTet al.: Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer.J. Clin. Oncol.2(33), 5100\u20135186 (2007).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_2_3_73_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.1939"},{"key":"e_1_3_2_3_74_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-0351"},{"key":"e_1_3_2_3_75_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605514"},{"key":"e_1_3_2_3_76_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23374"},{"key":"e_1_3_2_3_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2008.02.009"},{"key":"e_1_3_2_3_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2009.08.032"},{"key":"e_1_3_2_3_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2010.02.021"},{"key":"e_1_3_2_3_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70362-6"},{"key":"e_1_3_2_3_81_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djm086"},{"key":"e_1_3_2_3_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70112-3"},{"key":"e_1_3_2_3_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2010.01.011"},{"key":"e_1_3_2_3_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2007.01.038"},{"key":"e_1_3_2_3_85_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2009.05.031"},{"key":"e_1_3_2_3_86_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc052954"},{"key":"e_1_3_2_3_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2008.11.025"},{"key":"e_1_3_2_3_88_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2009.11.001"},{"issue":"15","key":"e_1_3_2_3_89_1","first-page":"204S","article-title":"Serious wound healing complications following surgery in patients with metastatic colorectal cancer receiving bevacizumab: results from the BriTE observational cohort study.","volume":"26","author":"Sugrue MM","year":"2008","unstructured":"Sugrue MM , PurdieDM, FengSet al.: Serious wound healing complications following surgery in patients with metastatic colorectal cancer receiving bevacizumab: results from the BriTE observational cohort study.J. Clin. Oncol.26(Suppl. 15), 204S (2008) (Abstract 4105).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_2_3_90_1","doi-asserted-by":"publisher","DOI":"10.1002\/jso.20301"},{"key":"e_1_3_2_4_2_1","unstructured":"National Comprehensive Cancer Network: The NCCN clinical practice guidelines in oncology ovarian cancer (Version 2.2010) www.nccn.org (Accessed 1 August 2010)"},{"key":"e_1_3_2_4_3_1","unstructured":"Sunitinib in recurrent and refractory ovarian fallopian tube and peritoneal carcinoma http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00768144?term=NCT00768144&rank=1"},{"key":"e_1_3_2_4_4_1","unstructured":"BIBF 1120 or placebo in combination with paclitaxel and carboplatin in first line treatment of ovarian cancer http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01015118?term=NCT01015118&rank=1 (Accessed 11 January 2010)"},{"key":"e_1_3_2_4_5_1","unstructured":"Study of oral ENMD-2076 administered to patients with ovarian cancer http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01104675?term=ENMD2076%2C+ovarian+cancer&rank=1 trialNCT01104675"},{"key":"e_1_3_2_4_6_1","unstructured":"FDA Advisory Committee Recommends against Bevacizumab for Metastatic Breast Cancer www.cancer.gov\/ncicancerbulletin\/072710\/page2"},{"key":"e_1_3_2_4_7_1","unstructured":"Avastin and erlotinib as first-line consolidation chemotherapy after carboplatin paclitaxel and avastin (CTA) induction therapy for advanced ovarian fallopian tube and primary peritoneal cancer and papillary serous mullerian tumors http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00520013"},{"key":"e_1_3_2_4_8_1","unstructured":"BIBF 1120 or placebo in combination with paclitaxel and carboplatin in first-line treatment of ovarian cancer http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01015118?term=NCT01015118&rank=1"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon.10.167","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:45:08Z","timestamp":1719125108000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon.10.167"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3,21]]},"references-count":97,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,3,31]]}},"alternative-id":["10.2217\/fon.10.167"],"URL":"https:\/\/doi.org\/10.2217\/fon.10.167","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,3,21]]}}}